Improved donor chimerism in relapse myelofibrosis post allogenic stem cell transplant with azacitidine and oral decitabine—First case report

eJHaem

article

Verna Cheung¹  Fotios V. Michelis³  Hassan Sibai¹ 

[1] Princess Margaret Cancer Centre;University of Toronto;Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network

关键词: allogenic stem cell transplant;    hypomethylating agent;    myeloid lineage chimerism;    primary myelofibrosis;   

DOI  :  10.1002/jha2.611

来源: Wiley

【 摘 要 】

To date, allogenic stem cell transplant (ASCT) remains the only potential curative option for patients with primary myelofibrosis (PMF). However, relapse rates and associated mortality remain a concern. A second ASCT may not be feasible due to advancing age, declined functional status, donor unavailability, toxicities associated with a second ASCT. Herein, we report the first case of utilizing initially azacitidine and subsequently oral decitabine + cedazuridine (decitabine), in the context of relapsed PMF post-ASCT. Utilizing both hypomethylating agents provided disease control and improved donor/myeloid lineage chimerism levels, and the patient also remained transfusion independent, with preserved functional status and quality of life.

【 授权许可】

Unknown